Business Wire

Ultivue Announces Co-Marketing and Co-Development Collaboration with Paige for AI-Powered Biomarker Imaging Solutions for Precision Medicine

Share

Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, and Paige, the global leader in AI-based diagnostic software in pathology, today announced a partnership to collaborate on the co-development and co-marketing of AI-powered spatial immunophenotype capabilities to pharmaceutical and research customers.

Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue’s novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels.

The Paige portfolio includes the Paige Platform, a comprehensive imaging solution composed of the FDA-cleared and CE-marked FullFocus™, an intuitive and responsive viewer for pathology scans that supports primary diagnosis together with a data management solution for storage of pathology scans. The fast, zero-footprint, scanner-agnostic viewer, storage capabilities and AI-based diagnostic software help pathologists review cases and support their overall workflow.

Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique platform agnostic solutions for use in both mIF imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.

“This collaboration with Paige is an exciting milestone for Ultivue as we consider the evolving impact of AI and deep learning tools on histopathological images in clinical settings,” said Jacques Corriveau, CEO, Ultivue. “Importantly, our aligned goals are to facilitate the decentralization and democratization of the generation and analysis of complex spatial data.”

“The combination of Ultivue’s robust biomarker detection capabilities and Paige’s AI-enabled computational pathology technology allows us to deliver new products that will elevate how immuno-oncology research is done today,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “By uniting two platform-agnostic technologies, we are well-positioned to enable broad adoption of our AI-powered biomarker imaging solutions.”

About Paige

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, M.D., and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product. For additional information, please visit: paige.ai, Twitter and LinkedIn.

About Ultivue

Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at ultivue.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ultivue
Adrian Arechiga Ph.D
Vice President Marketing
E. mail: adrian.arechiga@ultivue.com

Paige
Matt Houliston
Senior Director, Strategic Partnerships
E.mail: matt.houliston@paige.ai

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Anterra Capital: Pandemic and Food Price Inflation Fuel Investor Interest to Accelerate Transformation of the Food and Ag Sector18.5.2022 07:00:00 CEST | Press release

A crushing pandemic and, more recently, the Ukraine war have convinced investors more than ever that the world needs to radically change how it produces, distributes and consumes food, says Adam Anders, managing partner of the international food and agriculture specialist venture capital firm Anterra Capital (“Anterra”). Anders: “The pandemic highlighted the fragility and adverse health impacts of our current food system: soaring prices, empty shelves in stores; the fact that unhealthy diets are a major risk factor for getting Covid; that the way we treat farm animals could trigger the next pandemic. Post our final closing, the devastating impact of the Ukraine War on the global food supply has increased the awareness among investors even further. This, plus our focus on deploying proven biotech and digital solutions to shake up the lagging Food and Ag-sector, go a long way in explaining the higher than expected interest in our second fund.” Anterra is proud to announce the closing of

US Streaming Technology Giant Conviva Launches Full-Scale Continuous Measurement Analytics in Japan18.5.2022 03:00:00 CEST | Press release

Conviva (Headquartered at Foster City, California, USA; Japan Office: Chiyoda-ku, Tokyo; hereinafter referred to as Conviva or the Company), which provides continuous measurement analytics through real-time, server side sessionization of video streaming data, today announced the opening of the Japan office, which will serve as a base for sales and customer support in the rapidly-growing Japanese market. The Company also released a current State of Streaming Report for Japan highlighting key streaming trends in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517006275/en/ Conviva State of Streaming Japan Report (Graphic: Business Wire) “Conviva invented continuous measurement analytics for streaming video and has been driving the development of the global market including Japan with over 58 technology patents over the past decade,” comments Conviva CEO Keith Zubchevich. “Today, we are pleased to announce the est

Starr Insurance Companies Expands in Thailand17.5.2022 22:33:00 CEST | Press release

Starr Insurance Companies (Starr) announced an agreement with FPG Insurance Holdings Limited (HK) (FPG) and local Thai shareholders to purchase FPG Insurance Public Company Limited (FPG Thailand), a Thai non-life insurance company, together with local Thai parties. Starr’s investment will be held by its Bermuda insurance company, Starr Insurance & Reinsurance Limited. The transaction is expected to close in the second quarter of 2022, subject to certain customary closing conditions, including any necessary regulatory approvals. “Thailand is an important, fast-growing insurance market — one of the cornerstones of the Southeast Asia economy,” said Maurice R. Greenberg, Starr’s Chairman & CEO. “Asia is both commercially and culturally important to Starr, as we trace our roots to an American-owned company founded in Shanghai more than 100 years ago. We look forward to serving the needs of local Thai companies and consumers through this new insurance capability.” David Zuellig, FPG regional

Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE -related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting17.5.2022 22:15:00 CEST | Press release

Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C. Emendo presented pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo, showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect. “ELANE-based

Piper Sandler Advises PETRONAS Chemicals Group Berhad on Acquisition of Perstorp17.5.2022 19:59:00 CEST | Press release

Piper Sandler & Co. chemicals investment banking announced today that it has advised PETRONAS Chemicals Group Berhad (PCG) on its acquisition of Perstorp Holding AB. The transaction Enterprise Value is €2,300 million and base purchase price, less adjusted net debt, is €1,538 million. It is expected to close in Q3 2022 subject to customary closing conditions. PCG is the leading integrated chemicals producer in Malaysia and one of the largest in Southeast Asia. It operates a number of world-class production sites, which are fully vertically integrated from feedstock to downstream end-products. With a total combined production capacity of 12.8 million metric tons per annum (mtpa), it is involved primarily in manufacturing, marketing, and selling a diversified range of chemical products, including olefins, polymers, fertilizers, methanol and other basic chemicals and derivative products. Listed on Bursa Malaysia in 2010 and with more than three decades of experience in the chemicals indust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom